Medical Lab: Cost Per Test, Reagent Waste and Analyser Utilization

«We have four collection points and our own laboratory. We run about 14,000 tests a month, roughly ₴1,100,000. And at month-end eighty-five thousand is left. More collection points, more tests, and still no money for growth» — that's how Oleh, the owner of a medical laboratory network, opened our conversation.

Sound familiar? Queues in the morning, a courier moving samples between sites, analysers running non-stop, results landing in patients' apps. It looks like a well-oiled operation. Yet when you sit down to count what's actually yours, the number is disappointingly small.

The trouble is that a laboratory gets counted as a single pot: all patient and corporate payments go into one cauldron, and all reagent purchases, wages, site rents and logistics come out of the same one. While the numbers are blended, you can't see one simple thing: one test group yields 55% margin while another runs at a loss, because the reagent expires faster than you can collect samples.

This article is about breaking a laboratory down into individual tests and individual collection points. So you can see which test and which site genuinely bring in money, and what merely exists to round out the menu.

The Founder's Path: From One Room to a Network of Four Sites

Oleh started out as a laboratory physician and spent ten years working in someone else's lab. He opened his first room with a partner: one analyser, one nurse, a basic test menu, everything complex sent out to a partner lab.

Then came growth: a second site in a residential district, a third next to a clinic, a fourth in a neighbouring city. In-house biochemistry and haematology followed, along with courier logistics for samples and contracts with clinics and companies for occupational health screening.

And somewhere around the third site, the simple «revenue minus reagents minus wages» arithmetic stopped working. More tests, more expensive equipment, less free cash. Oleh had a lab information system with test counts, a reagent purchasing spreadsheet and a bank app. Three sources with the profit vanishing somewhere between them.

«I thought the cost of a test was the price of the reagent. When we counted write-offs, calibration runs and analyser downtime, it turned out to be twice that.»

How Money Actually Works in a Medical Laboratory

Before we get to what Oleh changed, let's break down what a laboratory's profit is made of. Because this is exactly where the money that «disappears» gets lost.

The Cost of a Test Isn't the Price of the Reagent

Let's count one test honestly. Reagent per test — ₴38. Tube, needle, label and collection consumables — ₴14. The nurse's time per visit — ₴12. The technician's time — ₴9. Analyser depreciation per test — ₴11. Sample logistics between site and lab — ₴6. That's ₴90 against a patient price of ₴160.

It looks decent: ₴70 of margin. But that's before site rent, administrators, licences, equipment service contracts and taxes — and before the most important item of all, which we'll cover next: reagent write-offs.

Reagents That Expire: A Laboratory's Quietest Cost

Reagents come in kits sized for a certain number of tests, with a shelf life once opened. If a kit covers 100 tests and you ran 40 before it expired, the rest is written off.

Which means your real cost per test isn't ₴38 of reagent but ₴95. Formally you «ran the test at the price of the reagent»; in practice you paid for 100 tests and sold 40. That's exactly how the rare tests a lab takes pride in become structurally unprofitable.

Add control runs and calibrations: they consume reagent too and bring in no revenue. In a small laboratory that can be a noticeable share of the reagent budget.

We kept widening the test menu to be more convenient. What we were actually doing was pouring money down the sink every month in the form of expired reagent.

Analyser Utilization: The Key Efficiency Metric

An analyser is an expensive asset that costs you the same whether it runs or sits. Lease or loan payments, the service contract, calibrations, floor space, trained staff — all fixed.

Compare two labs with identical equipment. The first runs 400 tests a day on the analyser, the second runs 120. Their running costs are nearly the same, so the second lab's cost per test is three times higher. The key number here isn't the number of sites or the length of the test menu, it's how many tests pass through each piece of equipment per shift.

Profit Per Collection Point: They All Look the Same Until You Count

A collection point means rent, a nurse, an administrator, consumables and utilities. Its income is visits times average ticket. Count them separately and it almost always turns out that one site feeds the network, another breaks even, and a third lives off the first two.

The reasons vary: a location with thin footfall, inflated rent, opening hours that miss the peak. But while profit is counted for the network as a whole, the weak site is invisible — the others simply subsidise it. We covered that kind of breakdown separately — margin by line, location and channel.

Outsourced Complex Tests: Pass-Through Margin

Whatever you don't run in-house goes to a partner laboratory. The patient pays you ₴900, you pay the partner ₴620, and ₴280 remains before collection and logistics.

It's a perfectly normal model, but it inflates turnover and distorts perception: half of that «revenue» is someone else's money passing through. If you don't separate outsourced tests from your own, your average margin looks lower than it is, and the effect of outsourcing on cash flow goes unnoticed.

Corporate Contracts: Stability on the Schedule, a Gap in the Cash

Contracts with companies for health screening and with clinics for ongoing service give you a predictable flow. But almost always with 30-day payment terms and a volume discount.

Reagents, meanwhile, are bought in advance, often prepaid, and wages go out twice a month. So you end up financing someone else's payment schedule with your own money. One large client paying late and the reagent order is postponed, forcing the lab to shorten its available test menu.

Life Before Finmap

Before he put things in order, Oleh lived roughly like this. He recognises these lines himself — and you might too.

• «More tests every month and the same free cash. Where it goes, I don't know.»
• «Our cost per test is approximate — reagent price plus a bit on top.»
• «Which site is profitable, I couldn't say exactly. We count the network as a whole.»
• «We write reagents off sometimes, but what that adds up to over a year, nobody has counted.»
• «Corporate clients pay late, and every time it hits our purchasing.»

Every one of these lines is about the same thing: the laboratory is measured by total revenue instead of cost per test and profit per site. The moment you break the numbers apart, the picture becomes almost uncomfortably clear.

How Oleh Put Things in Order

The turning point was mundane: the monthly reagent order was due and there wasn't enough free cash — in a month that set a record for test volume. Oleh sat down and realised he wasn't losing money, he simply couldn't see his own. What he needed wasn't a fifth collection point, it was order in the finances, so he could see where money goes every day.

That's how he came to Finmap. The brief was simple: see margin by test group and by site, build reagent write-offs into the cost, and plan purchasing against real incoming cash. Setting it up took a few evenings.

• Every site is its own line of business. Revenue, rent, wages and consumables attach to a specific address, so each site's profit is visible.
• Test groups kept separate. In-house and outsourced tests are split, so pass-through money doesn't inflate revenue.
• Reagents counted with write-offs. The cost includes not only the reagent used but the portion that expired unused.
• Bank integration and auto-import. Patient payments, corporate transfers and purchases pull in automatically.
• Payment calendar. Reagent orders, wages, rent and equipment leases laid out in advance — a gap shows up two weeks ahead.

What Oleh particularly liked is that Finmap speaks the owner's language rather than the accountant's: not «trial balance,» but «this site yields ₴40,000 a month and that one is minus ₴6,000.» And that the AI adviser flags the odd stuff by itself: «reagent spend is up 30% while test volume is up 8%.»

I wasn't short of patients. I was short of an honest cost per test. Once I saw it, half the decisions made themselves.

The Finances Now

In four months with Finmap, Oleh didn't open a single new site — he closed one. And net profit, on slightly lower turnover, nearly doubled. Here's what changed.

How did he get there? He closed the site that had run at a loss for two years on expensive rent and thin footfall. He removed eight rare tests where reagent write-offs ate the entire margin and moved them to the partner lab. He changed the purchasing schedule so kits are opened against real sample flow. And he introduced prepayment for new corporate contracts.

An insight for business owners. In a laboratory, profit hides not in the number of tests but in the honest cost of each one — including what expired unused. Two labs with identical equipment can differ twofold in profit: one knows its margin by group and by site, the other watches total revenue.

A Few Closing Tips

• Cost a test in full: reagent, consumables, labour, depreciation, logistics.
• Always include reagent write-offs and calibration runs — that's real money.
• Read profit per collection point, not for the network as a whole.
• Watch analyser utilization: underused equipment makes every test more expensive.
• Separate outsourced tests from your own so pass-through money isn't mistaken for revenue.
• Plan reagent purchasing against a payment calendar rather than the balance in the account.

Money Doesn't Disappear. You Just Don't See It.

Money in a laboratory doesn't evaporate. It dissolves into expired reagents, underused equipment, weak sites and corporate payment terms while you watch test counts and total revenue. The moment you break it down by group and by address, you can see what feeds the network and what survives on the others.

You don't need more collection points. You need to see which test and which site actually bring in money — and to have the kind of order in your finances where that's visible every day, not guessed at once a year.

Try looking at your laboratory in a new way — and within the first month you'll see what feeds you and what is quietly eating you.